Aaron Dane

2.6k citations

52 papers · 1.9k indexed · 1 hit paper · h-index 26

Impact in

Applied Microbiology and Biotechnology top 1%
- Antibiotic Use and Resistance
Molecular Medicine top 1%
- Antibiotic Resistance in Bacteria

Papers in ⓘ

Molecular Medicine 10
- Antibiotic Resistance in Bacteria 10
Pharmacology 17
- Antibiotics Pharmacokinetics and Efficacy 12

Co-authors: Mike J. Warwick (9 shared papers)Paul Martin (9 shared papers)Dennis W. Schneck (9 shared papers)Ali Raza (3 shared papers)Eva M. Lenz (1 shared paper)P. J. Phillips (1 shared paper)Steve Hill (1 shared paper)Mireille Cantarini (2 shared papers)
Journals: Open Forum Infectious Diseases (7 papers)Antimicrobial Agents and Chemotherapy (6 papers)Pharmaceutical Statistics (5 papers)Clinical Infectious Diseases (4 papers)The Journal of Clinical Pharmacology (4 papers)
Partner nations: United Kingdom United States Germany

In The Last Decade

Aaron Dane

52 papers receiving 1.9k citations

Hit Papers

align trajectories log scale

Cefepime–Taniborbactam in Complicated Urinary Tract Infection 2024 · 67 citations

Peers

Countries citing papers authored by Aaron Dane

Since Specialization

Citations

This map shows the geographic impact of Aaron Dane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron Dane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron Dane more than expected).

Fields of papers citing papers by Aaron Dane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron Dane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron Dane. The network helps show where Aaron Dane may publish in the future.

Co-authors

The 25 scholars most cited alongside Aaron Dane, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aaron Dane Line = papers co-authored together Aaron Dane links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 52 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers Clinical Therapeutics ·Paul Martin, Mike J. Warwick, Aaron Dane, Steve Hill, Petrina B. Giles, P. J. Phillips, Eva M. Lenz	2003	233
2	Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers Clinical Pharmacokinetics ·Helen Swaisland, Alison Laight, Lesley E. Stafford, Helen Jones, Charles Morris, Aaron Dane, Roger Yates	2001	101
3	Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial Clinical Infectious Diseases ·Keith S. Kaye, Louis B. Rice, Aaron Dane, V.P. Stus, Olexiy Sagan, Elena Fedosiuk, Anita Das, David Skarinsky, Paul B. Eckburg, Evelyn J. Ellis‐Grosse	2019	100
4	A comprehensive regulatory framework to address the unmet need for new antibacterial treatments The Lancet Infectious Diseases ·John Rex, Barry I. Eisenstein, Jeff Alder, Mark Goldberger, Robert Meyer, Aaron Dane, Ian R. Friedland, Charles Knirsch, Wendy R. Sanhai, John Tomayko, Cindy Lancaster, Jennifer Jackson	2013	92
5	The effect of fluconazole on the pharmacokinetics of rosuvastatin European Journal of Clinical Pharmacology ·Kevin D. Cooper, Paul Martin, Aaron Dane, Mike J. Warwick, Dennis W. Schneck, Mireille Cantarini	2002	92
6	An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers Clinical Therapeutics ·Paul Martin, Aaron Dane, Dennis W. Schneck, Michael J. Warwick	2003	91
7	No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG‐CoA Reductase Inhibitor The Journal of Clinical Pharmacology ·Paul Martin, Aaron Dane, O.M. Nwose, Dennis W. Schneck, Mike J. Warwick	2002	80
8	The effect of erythromycin on the pharmacokinetics of rosuvastatin European Journal of Clinical Pharmacology ·K. J. Cooper, Paul Martin, Aaron Dane, Mike J. Warwick, Ali Raza, Dennis W. Schneck	2003	77
9	Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects British Journal of Clinical Pharmacology ·K. J. Cooper, Paul Martin, Aaron Dane, Mike J. Warwick, Ali Raza, Dennis W. Schneck	2003	77
10	Cefepime–Taniborbactam in Complicated Urinary Tract Infection New England Journal of Medicine ·Florian Wagenlehner, Leanne B. Gasink, Paul C. McGovern, Greg Moeck, Patrick McLeroth, MaryBeth Dorr, Aaron Dane, Tim Henkel Hit paper breakdown →	2024	67
11	No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor The Journal of Clinical Pharmacology ·Paul Martín, Aaron Dane, O.M. Nwose, Dennis W. Schneck, Mike J. Warwick	2002	64
12	Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522 Atherosclerosis ·Mike J. Warwick, Aaron Dane, Ali Raza, Dennis W. Schneck	2000	57
13	Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection New England Journal of Medicine ·Paul B. Eckburg, Lori A Muir, Ian A. Critchley, Susannah M. Walpole, Hanna Kwak, Anne-Marie Phelan, Gary Moore, Akash Jain, Tim Keutzer, Aaron Dane, David Melnick, Angela K. Talley	2022	56
14	Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia The Journal of Infectious Diseases ·George H. Talbot, Anita Das, Stephanie S. Cush, Aaron Dane, Michele Wible, Roger Echols, Antoní Torres, Sue Cammarata, John Rex, John H. Powers, Thomas Fleming, Jeffrey S Loutit, Steve Hoffmann	2018	53
15	A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers Clinical Therapeutics ·Paul Martin, Mike J. Warwick, Aaron Dane, Mireille Cantarini	2003	48
16	Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance Clinical Infectious Diseases ·John Rex, George H. Talbot, Mark Goldberger, Barry I. Eisenstein, Roger Echols, John Tomayko, Michael N. Dudley, Aaron Dane	2017	47
17	Randomized Dose-Response Study of Rosuvastatin in Japanese Patients With Hypercholesterolemia Journal of Atherosclerosis and Thrombosis ·Yasushi Saitō, Yuichiro Goto, Aaron Dane, Kristina Strutt, Ali Raza	2003	47
18	No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers The Journal of Clinical Pharmacology ·Paul Martin, John Kemp, Aaron Dane, Mike J. Warwick, Dennis W. Schneck	2002	42
19	Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections Antimicrobial Agents and Chemotherapy ·Laura McEntee, Adam Johnson, Nicola Farrington, Jennifer Unsworth, Aaron Dane, Akash Jain, Nicole Cotroneo, Ian A. Critchley, David Melnick, Thomas Parr, Paul G. Ambrose, Shampa Das, William Hope	2019	39
20	First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections Antimicrobial Agents and Chemotherapy ·Angela K. Talley, Archie Thurston, Grayson Moore, Vipul K. Gupta, Myriah M Satterfield, Erika Manyak, S. Stokes, Aaron Dane, David Melnick	2021	39

About Aaron Dane

Aaron Dane is a scholar working on Molecular Medicine, Pharmacology, Statistics and Probability, Applied Microbiology and Biotechnology and Urology, having authored 52 papers that have together received 1.9k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (13 papers), Antibiotics Pharmacokinetics and Efficacy (12 papers), Antibiotic Resistance in Bacteria (10 papers), Urinary Tract Infections Management (7 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers), Statistical Methods in Clinical Trials (5 papers) and Pharmaceutical Economics and Policy (5 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (178 citations), Molecular Medicine (416 citations), Pharmacology (214 citations), Pharmacology (396 citations) and Surgery (614 citations). Aaron Dane has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Mike J. Warwick, Paul Martin, Dennis W. Schneck, Ali Raza, Eva M. Lenz, P. J. Phillips, Steve Hill, Mireille Cantarini, John Rex and John Kemp. Their work appears in journals such as Open Forum Infectious Diseases, Antimicrobial Agents and Chemotherapy, Pharmaceutical Statistics, Clinical Infectious Diseases and The Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact